Fellow of the Chartered Institute of Patent Attorneys (UK) (1992); European Patent Attorney (1992); BSc (Hons) Biochemistry.
Paul has almost 30 years experience of working in Intellectual property in the Life Sciences field. He began his career working in private practice in the 1980s, during the early days of the Biotech industry. He then spent several years in house in a multinational pharmaceutical company, which gave him a useful perspective on the commercial importance of IP, both from the point of view of protecting new products and also clearing a path for a company’s commercial activities. He then returned to private practice and spent over 20 years at a major London firm, 17 of them as a partner.
Paul has worked for individual clients, for start up companies and SMEs, for Universities and for larger corporate clients. His experience ranges across all areas of IP including, initial drafting and prosecution of patents, developing and managing patent portfolios, developing IP strategies, IP due diligence and IP transactional work, including stock exchange listings. As well as these he also has a wealth of experience in EPO Opposition and Appeal proceedings.
In terms of technology, Paul’s practice covers all the “conventional” aspects of Life Sciences, from NCEs through gene technologies, immunology, pharmaceutical formulations, drug delivery technologies, manufacturing processes and medical devices. Particular highlights include working on the original PCR patent filings before the EPO, the Harvard Mouse case, which helped define the patentability of animals before the EPO and working on the original Roslin Institute case covering the cloning of Dolly the sheep.